Using light therapy to prevent nerve pain from chemotherapy
Prevention of Neuropathic Pain From Oxaliplatin by Photobiomodulation
This study is testing whether light therapy can help reduce nerve pain in people with gastrointestinal cancer who are receiving chemotherapy.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 70 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Saint-Gregoire Private Hospital Center Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Saint-Grégoire) |
| Trial ID | NCT06199115 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effectiveness of photobiomodulation, a non-pharmacological intervention, in reducing neuropathic pain caused by oxaliplatin-based chemotherapy in patients with gastrointestinal cancer. Participants will receive light therapy to assess its impact on alleviating painful peripheral neuropathy that develops during treatment. The study aims to provide a potential alternative to pharmacological treatments for managing chemotherapy-induced neurotoxicity. By focusing on patients who have recently been diagnosed with digestive cancer and are undergoing oxaliplatin treatment, the study seeks to address a significant side effect of cancer therapy.
Who should consider this trial
Good fit: Ideal candidates are adults recently diagnosed with digestive cancer who are scheduled to receive 12 cycles of oxaliplatin.
Not a fit: Patients with a history of neuropathy, those receiving symptomatic pain treatment, or individuals with certain comorbidities may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly reduce the incidence and severity of neuropathic pain in patients undergoing chemotherapy.
How similar studies have performed: While non-pharmacological interventions for chemotherapy-induced neurotoxicity have shown potential benefits, the specific use of photobiomodulation in this context is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Recent diagnosis of digestive cancer * 12 planned cycles of oxaliplatin * Ability to understand and willingness to sign an informed consent form before starting any study procedures * Patient benefiting from French health insurance Exclusion Criteria: * History of neuropathy before the start of the study, * Symptomatic treatment of pain (or neuropathic pain), * Patient with a psychotic disorder, * Patient with diabetic neuropathy, * Patient with metastatic cancer * Patient with renal insufficiency, * Adults under guardianship or curatorship, * Vulnerable people
Where this trial is running
Saint-Grégoire
- CHP Saint-Grégoire — Saint-Grégoire, France (Recruiting)
Study contacts
- Principal investigator: Morgane Pihan — CHP Saint-Grégoire
- Study coordinator: Morgane Pihan, MD
- Email: mpihan@vivalto-sante.com
- Phone: +33 2 93 23 97 80
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.